BUZZ - General Dynamics shares rise due to better-than-expected Q3 results; Gulfstream and ship orders drive new order growth
路透社2026/10/30 11:41October 30 - ** After defense contractor General Dynamics (GD.N) released its third-quarter earnings report, its share price rose about 4% to $385.01
** According to data compiled by London Stock Exchange Group (LSEG), third-quarter revenue was $14.57 billion, higher than the analyst average forecast of $13.73 billion
** Third-quarter earnings per share (EPS) was $4.49, exceeding the expected $4.13 and up 15.7% year over year
** Driven by large orders for Virginia-class and Columbia-class submarines, the backlog surged from $136.5 billion in the second quarter to $220.3 billion
** The company's overall book-to-bill ratio was 6.8:1
** Revenue in the Marine Systems division rose 21.1%; operating margin for the Aerospace business expanded from 13.3% to 14.5%
** Free cash flow was $1.23 billion, down from $1.90 billion in the same period last year, while capital expenditures more than doubled to $481 million
** As of the close of the previous trading day, the share price had risen 10.15% year to date
(To assist non-native English speakers, Reuters has automated the translation of its report into several other languages. Because automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation. The automated translation is provided solely for the convenience of readers. Reuters accepts no responsibility for any damages or losses arising from the use of this automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. stocks opened with tech sell-off continuing, Intel plunges 25.7%.
BUZZ-H2O America stock falls due to $325 million convertible issuance
BUZZ - Acumen shares plunge after mid-stage trial failure for Alzheimer's drug

